As the COVID-19 pandemic continues to evolve, inflammatory bowel disease
(IBD) specialists worldwide have been required to address the unique
challenges faced by their patients, particularly concerning the risks associated
with infection and the management of immunosuppressive therapies. This review
aims to summarize the most current evidence and expert opinions
regarding the intersection of IBD management and the COVID-19 pandemic.